ORCID as entered in ROS
https://orcid.org/0000-0002-4257-7620
Select Publications
Journal articles
, 2005, 'Duration and frequency of haemodialysis therapy', Nephrology, 10, http://dx.doi.org/10.1111/j.1440-1797.2005.00464_4.x
, 2005, 'Haemodialysis anticoagulation and adequacy', Nephrology, 10, http://dx.doi.org/10.1111/j.1440-1797.2005.00464_6.x
, 2005, 'Water quality for haemodialysis', Nephrology, 10, http://dx.doi.org/10.1111/j.1440-1797.2005.00464_5.x
, 2003, 'Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells', Kidney and Blood Pressure Research, 26, pp. 27 - 33, http://dx.doi.org/10.1159/000069761
, 2003, 'Accelerated progression of calcific aortic stenosis in dialysis patients.', Nephron Clinical Practice, 94, pp. c40 - c45, http://dx.doi.org/10.1159/000071280
, 2002, 'Factors affecting outcome after percutaneous renal artery stent insertion', Journal of Nephrology, 15, pp. 649 - 654
, 2002, 'ACCELERATED PROGRESSION OF CALCIFIC AORTIC STENOSIS IN DIALYSIS PATIENTS', Nephrology, 7, pp. A106 - A106, http://dx.doi.org/10.1046/j.1440-1797.2002.00007-1-106.x
, 2002, 'LONG TERM OUTCOMES OF STENT INSERTION FOR RENAL ARTERY STENOSIS', Nephrology, 7, http://dx.doi.org/10.1046/j.1440-1797.2002.00007-1-7.x
, 2002, 'LOVASTATIN DOWNREGULATES RENAL MYOFIBROBLAST FUNCTION IN VITRO', Nephrology, 7, http://dx.doi.org/10.1046/j.1440-1797.2002.00007-1-2.x
, 2002, 'PARATHYROID HORMONE HAS A PROSCLEROTIC EFFECT ON VASCULAR SMOOTH MUSCLE CELLS', Nephrology, 7, http://dx.doi.org/10.1046/j.1440-1797.2002.00007-1-69.x
, 2001, 'Pharmacological intervention in renal fibrosis and vascular sclerosis', Journal of Nephrology, 14, pp. 332 - 339
, 2001, 'Treatment of renovascular disease with percutaneous stent insertion: Long-term outcomes', Australasian Radiology, 45, pp. 438 - 443, http://dx.doi.org/10.1046/j.1440-1673.2001.00953.x
, 1999, 'Haemolytic uraemic syndrome and prostatic cancer', Australian and New Zealand Journal of Medicine, 29, pp. 383 - 384, http://dx.doi.org/10.1111/j.1445-5994.1999.tb00730.x
Conference Papers
, 2023, 'A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF BION-1301 IN ADULTS WITH IGA NEPHROPATHY', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ITALY, Milan, pp. I398 - I399, presented at
, 2023, 'HEART FAILURE IN ASCEND-ND AND ASCEND-D', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ITALY, Milan, pp. I453 - I455, presented at
, 2023, 'LONG-TERM SAFETY OF HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS IN CHRONIC KIDNEY DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMISED CONTROLLED TRIALS', in NEPHROLOGY, WILEY, pp. 12 - 12
, 2022, 'Assessment Of Associations Between Hypoglycemia And Cardiovascular Outcomes In The Randomized CARMELINA And CAROLINA Trials Of The Antihyperglycemic Medication Linagliptin', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at
, 2022, 'BASELINE CHARACTERISTICS OF THE FLOW TRIAL POPULATION: KIDNEY OUTCOMES TRIAL WITH ONCE-WEEKLY SEMAGLUTIDE IN PEOPLE WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, FRANCE, Paris, pp. I893 - I894, presented at
, 2022, 'A Phase 2b Randomized Controlled Trial of Selonsertib in Moderate to Severe Diabetic Kidney Disease (MOSAIC)', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 28 - 28
, 2022, 'A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients With IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 799 - 799
, 2022, 'Effect of Canagliflozin on Markers of Hepatic Steatosis and Fibrosis in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 673 - 674
, 2022, 'Effect of Iptacopan on Proteinuria and Complement Biomarkers Over Time in IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 33 - 34
, 2022, 'Gene Polymorphism in Organic Anion Transporters Determine the Long-Term Efficacy and Safety of Atrasentan in Patients With Type 2 Diabetes and CKD', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 116 - 116
, 2022, 'Lower Glomerular Filtration Rate and Higher Albuminuria Are Associated With Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 297 - 298
, 2022, 'On-Treatment Cancer Safety Events With Daprodustat vs. Erythropoiesis-Stimulating Agents: Post Hoc Analyses of ASCEND-ND and ASCEND-D', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 631 - 631
, 2021, 'Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, pp. 2647 - 2647, http://dx.doi.org/10.26190/unsworks/28409
, 2021, 'Urate-lowering Therapy for Prevention of Gout: Prespecified Analyses from the CKD-FIX Trial', in ARTHRITIS & RHEUMATOLOGY, WILEY, pp. 1372 - 1373, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000744545202187&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2021, 'ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, presented at
, 2021, 'Sglt2 inhibition for ckd and cardiovascular disease in type 2 diabetes: Report of a scientific workshop sponsored by the national kidney foundation', in Diabetes, pp. 1 - 16, http://dx.doi.org/10.2337/dbi20-0040
, 2021, 'ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B2 - B3
, 2021, 'Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 47 - 47
, 2021, 'Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 263 - 264
, 2021, 'IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 190 - 190
, 2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Trial', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. 728 - 728
, 2021, 'The TESTING Study: Steroids vs. Placebo in High Risk IgA Nephropathy', in JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, AMER SOC NEPHROLOGY, pp. B1 - B1
, 2020, 'THE EFFECTS OF ALLOPURINOL ON THE PROGRESSION OF CHRONIC KIDNEY DISEASE ACCORDING TO BASELINE KIDNEY FUNCTION: PRE-SPECIFIED ANALYSES OF THE CKD-FIX TRIAL', in NEPHROLOGY, WILEY, pp. 60 - 60, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
, 2020, 'Renoprotection with semaglutide and liraglutide: Direct or indirect effects?', in DIABETOLOGIA, SPRINGER, ELECTR NETWORK, pp. S67 - S68, presented at
, 2020, 'Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop', in American Journal of Kidney Diseases, pp. 109 - 120, http://dx.doi.org/10.1053/j.ajkd.2020.01.022
, 2020, 'EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 152 - 152, presented at
, 2020, 'REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, ELECTR NETWORK, pp. 183 - 183, presented at
, 2020, 'Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency', in American Journal of Kidney Diseases, pp. 84 - 104, http://dx.doi.org/10.1053/j.ajkd.2019.06.009
, 2019, 'Interrelationship between hypoglycemia and CV and mortality outcomes in type 2 diabetes in the CARMELINA Trial', in DIABETES-METABOLISM RESEARCH AND REVIEWS, WILEY, PEOPLES R CHINA, Xiamen, presented at
, 2019, 'Canagliflozin Reduces Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Chronic Kidney Disease Regardless of Baseline HbA1c, Including Those With HbA1c < 7%: Results From the CREDENCE Trial', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, PA, Philadelphia, presented at
, 2019, 'First plus recurrent CV and hospitalization events in the CArdiovascular and Renal Microvascular outcomE study with LINAgliptin (CARMELINA) in patients with type 2 diabetes and cardiorenal disease', in EUROPEAN HEART JOURNAL, OXFORD UNIV PRESS, FRANCE, Paris, pp. 3877 - 3877, presented at
, 2018, 'Effects of the DPP-4 Inhibitor Linagliptin on Heart Failure Outcomes in Patients With Type 2 Diabetes and Cardio-Renal Disease in CARMELINA', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, pp. E771 - E772, presented at
, 2018, 'Canagliflozin and cardiovascular outcomes in patients with chronic kidney disease', in DIABETOLOGIA, SPRINGER, GERMANY, Berlin, pp. S39 - S39, presented at
, 2018, 'Acute Increase in Creatinine after Starting ACE Inhibitor and Vascular Events and Premature Death in Patients with Type 2 Diabetes-The ADVANCE Trial', in DIABETES, AMER DIABETES ASSOC, FL, Orlando, presented at
, 2017, 'Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events in Type 2 Diabetes: Results From the CANVAS Program', in CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, CA, Anaheim, pp. E454 - E455, presented at
, 2017, 'CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk', in DIABETES, AMER DIABETES ASSOC, CA, San Diego, pp. A344 - A344, presented at
, 2017, 'EFFECTS OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL', in NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIV PRESS, pp. 12 - 12
Filter by type
https://orcid.org/0000-0002-4257-7620